{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:11:37Z","timestamp":1793247097664,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02520-x","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:52:40Z","timestamp":1739325160000},"page":"888-898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunotherapy targeting a leader sequence cathepsin G-derived peptide"],"prefix":"10.1038","volume":"39","author":[{"given":"Chunhua","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pariya","family":"Sukhumalchandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Kerros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Torikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik","family":"Patchametla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Wiederschain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine L. C.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-1715","authenticated-orcid":false,"given":"Jeffrey","family":"Molldrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-4377","authenticated-orcid":false,"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2520_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00262-021-02993-6","volume":"71","author":"S Holmberg-Thyden","year":"2022","unstructured":"Holmberg-Thyden S, Dufva IH, Gang AO, Breinholt MF, Schejbel L, Andersen MK, et al. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome\u2014a phase I clinical trial. Cancer Immunol Immunother. 2022;71:433\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"2520_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017;31:697\u2013704.","journal-title":"Leukemia"},{"key":"2520_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236\u201342.","journal-title":"Blood"},{"key":"2520_CR4","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","volume":"90","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529\u201334.","journal-title":"Blood"},{"key":"2520_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018\u201323.","journal-title":"Nat Med"},{"key":"2520_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/1078-0432.CCR-12-2753","volume":"19","author":"M Zhang","year":"2013","unstructured":"Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, et al. A novel HLA-A*0201 restricted peptide derived from cathepsin g is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013;19:247\u201357.","journal-title":"Clin Cancer Res"},{"key":"2520_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/leu.2016.249","volume":"31","author":"G Alatrash","year":"2017","unstructured":"Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, et al. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017;31:234\u20137.","journal-title":"Leukemia"},{"key":"2520_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jcyt.2021.05.003","volume":"23","author":"S Lu","year":"2021","unstructured":"Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, et al. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy. 2021;23:793\u20138.","journal-title":"Cytotherapy"},{"key":"2520_CR9","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","volume":"89","author":"N Borregaard","year":"1997","unstructured":"Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503\u201321.","journal-title":"Blood"},{"key":"2520_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1126\/science.1546329","volume":"255","author":"RA Henderson","year":"1992","unstructured":"Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255:1264\u20136.","journal-title":"Science"},{"key":"2520_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/356443a0","volume":"356","author":"ML Wei","year":"1992","unstructured":"Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443\u20136.","journal-title":"Nature"},{"key":"2520_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/eji.200838136","volume":"38","author":"AO Weinzierl","year":"2008","unstructured":"Weinzierl AO, Rudolf D, Hillen N, Tenzer S, van Endert P, Schild H, et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol. 2008;38:1503\u201310.","journal-title":"Eur J Immunol"},{"key":"2520_CR13","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","volume":"6","author":"H Kinoshita","year":"2022","unstructured":"Kinoshita H, Cooke KR, Grant M, Stanojevic M, Cruz CR, Keller M, et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 2022;6:2520\u201334.","journal-title":"Blood Adv"},{"key":"2520_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9:eadf3700.","journal-title":"Sci Adv"},{"key":"2520_CR15","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"2520_CR16","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood.2020009471","volume":"137","author":"PD Lulla","year":"2021","unstructured":"Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood. 2021;137:2585\u201397.","journal-title":"Blood"},{"key":"2520_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1600-065X.1998.tb01199.x","volume":"163","author":"SJ Davis","year":"1998","unstructured":"Davis SJ, Ikemizu S, Wild MK, van der Merwe PA. CD2 and the nature of protein interactions mediating cell-cell recognition. Immunol Rev. 1998;163:217\u201336.","journal-title":"Immunol Rev"},{"key":"2520_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1146\/annurev.immunol.16.1.523","volume":"16","author":"MM Davis","year":"1998","unstructured":"Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1998;16:523\u201344.","journal-title":"Annu Rev Immunol"},{"key":"2520_CR19","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","volume":"117","author":"A Sergeeva","year":"2011","unstructured":"Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011;117:4262\u201372.","journal-title":"Blood"},{"key":"2520_CR20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2016.57","volume":"30","author":"A Sergeeva","year":"2016","unstructured":"Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, et al. Activity of 8F4, a T-cell receptor-like anti-PR1\/HLA-A2 antibody, against primary human AML in vivo. Leukemia. 2016;30:1475\u201384.","journal-title":"Leukemia"},{"key":"2520_CR21","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.177.6.4187","volume":"177","author":"VP Wittman","year":"2006","unstructured":"Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177:4187\u201395.","journal-title":"J Immunol"},{"key":"2520_CR22","doi-asserted-by":"publisher","first-page":"176ra133","DOI":"10.1126\/scitranslmed.3005661","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5:176ra133.","journal-title":"Sci Transl Med"},{"key":"2520_CR23","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","volume":"123","author":"L Dubrovsky","year":"2014","unstructured":"Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 2014;123:3296\u2013304.","journal-title":"Blood"},{"key":"2520_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway JB, Presta LG, Carter P. Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617\u201321.","journal-title":"Protein Eng"},{"key":"2520_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, et al. Design and production of bispecific antibodies. Antibodies (Basel). 2019;8:43.","journal-title":"Antibodies (Basel)"},{"key":"2520_CR26","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/s41375-023-02010-y","volume":"37","author":"Z Tian","year":"2023","unstructured":"Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, et al. Preclinical development of 1B7\/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 2023;37:2006\u201316.","journal-title":"Leukemia"},{"key":"2520_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","volume":"154","author":"LD Shultz","year":"1995","unstructured":"Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J Immunol. 1995;154:180\u201391.","journal-title":"J Immunol"},{"key":"2520_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807\u201315.","journal-title":"Nat Med"},{"key":"2520_CR29","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-18-1527","volume":"25","author":"G Alatrash","year":"2019","unstructured":"Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, et al. Fucosylation Enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Cancer Res. 2019;25:2610\u201320.","journal-title":"Clin Cancer Res"},{"key":"2520_CR30","doi-asserted-by":"publisher","first-page":"e22939","DOI":"10.1371\/journal.pone.0022939","volume":"6","author":"TG Rodriguez-Cruz","year":"2011","unstructured":"Rodriguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, et al. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011;6:e22939.","journal-title":"PLoS One"},{"key":"2520_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4161\/mabs.23539","volume":"5","author":"K Frese","year":"2013","unstructured":"Frese K, Eisenmann M, Ostendorp R, Brocks B, Pabst S. An automated immunoassay for early specificity profiling of antibodies. MAbs. 2013;5:279\u201387.","journal-title":"MAbs"},{"key":"2520_CR32","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.4049\/jimmunol.0902414","volume":"184","author":"B Verma","year":"2010","unstructured":"Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, et al. TCR mimic monoclonal antibody targets a specific peptide\/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184:2156\u201365.","journal-title":"J Immunol"},{"key":"2520_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WY Hwang","year":"2005","unstructured":"Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3\u201310.","journal-title":"Methods"},{"key":"2520_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","volume":"20","author":"WR Strohl","year":"2009","unstructured":"Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20:685\u201391.","journal-title":"Curr Opin Biotechnol"},{"key":"2520_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470\u201381.","journal-title":"Cancer"},{"key":"2520_CR36","doi-asserted-by":"publisher","first-page":"e004035","DOI":"10.1136\/jitc-2021-004035","volume":"10","author":"X Liu","year":"2022","unstructured":"Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J, et al. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy. J Immunother Cancer. 2022;10:e004035.","journal-title":"J Immunother Cancer"},{"key":"2520_CR37","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.3389\/fimmu.2018.03153","volume":"9","author":"AC Herrmann","year":"2018","unstructured":"Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, et al. A novel T-cell engaging Bi-specific antibody targeting the leukemia antigen PR1\/HLA-A2. Front Immunol. 2018;9:3153.","journal-title":"Front Immunol"},{"key":"2520_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/leu.2008.391","volume":"23","author":"S Hoves","year":"2009","unstructured":"Hoves S, Aigner M, Pfeiffer C, Laumer M, Obermann EC, Mackensen A. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray. Leukemia. 2009;23:877\u201385.","journal-title":"Leukemia"},{"key":"2520_CR39","first-page":"1721","volume":"9","author":"B Seliger","year":"2003","unstructured":"Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res. 2003;9:1721\u20137.","journal-title":"Clin Cancer Res"},{"key":"2520_CR40","doi-asserted-by":"publisher","first-page":"18763","DOI":"10.1074\/jbc.M511525200","volume":"281","author":"CC Chang","year":"2006","unstructured":"Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem. 2006;281:18763\u201373.","journal-title":"J Biol Chem"},{"key":"2520_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","volume":"57","author":"AM Mehta","year":"2008","unstructured":"Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57:197\u2013206.","journal-title":"Cancer Immunol Immunother"},{"key":"2520_CR42","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-05-2750","volume":"12","author":"RL Ferris","year":"2006","unstructured":"Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890\u20135.","journal-title":"Clin Cancer Res"},{"key":"2520_CR43","doi-asserted-by":"publisher","first-page":"e97805","DOI":"10.1172\/jci.insight.97805","volume":"3","author":"M Ahmed","year":"2018","unstructured":"Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, et al. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3:e97805.","journal-title":"JCI Insight"},{"key":"2520_CR44","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1182\/blood.V90.12.4938","volume":"90","author":"KP Papadopoulos","year":"1997","unstructured":"Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood. 1997;90:4938\u201346.","journal-title":"Blood"},{"key":"2520_CR45","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3389\/fimmu.2017.01975","volume":"8","author":"M Khan","year":"2017","unstructured":"Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, et al. Cathepsin G is expressed by acute lymphoblastic leukemia and is a potential immunotherapeutic target. Front Immunol. 2017;8:1975.","journal-title":"Front Immunol"},{"key":"2520_CR46","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1158\/1078-0432.CCR-04-2363","volume":"11","author":"H Fujiwara","year":"2005","unstructured":"Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res. 2005;11:4495\u2013503.","journal-title":"Clin Cancer Res"},{"key":"2520_CR47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ab.2012.01.033","volume":"423","author":"E Gorodkiewicz","year":"2012","unstructured":"Gorodkiewicz E, Sienczyk M, Regulska E, Grzywa R, Pietrusewicz E, Lesner A, et al. Surface plasmon resonance imaging biosensor for cathepsin G based on a potent inhibitor: development and applications. Anal Biochem. 2012;423:218\u201323.","journal-title":"Anal Biochem"},{"key":"2520_CR48","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/jcp.40.6.699-b","volume":"40","author":"J Crocker","year":"1987","unstructured":"Crocker J, Skilbeck N. Granulocyte markers cathepsin G and leukocyte elastase are rarely observed in Reed-Sternberg and Hodgkin\u2019s cells. J Clin Pathol. 1987;40:699\u2013700.","journal-title":"J Clin Pathol"},{"key":"2520_CR49","doi-asserted-by":"publisher","first-page":"35341","DOI":"10.1074\/jbc.M112.385617","volume":"287","author":"AD Gregory","year":"2012","unstructured":"Gregory AD, Hale P, Perlmutter DH, Houghton AM. Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem. 2012;287:35341\u201350.","journal-title":"J Biol Chem"},{"key":"2520_CR50","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.4049\/jimmunol.1201221","volume":"189","author":"G Alatrash","year":"2012","unstructured":"Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, et al. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012;189:5476\u201384.","journal-title":"J Immunol"},{"key":"2520_CR51","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/0008-5472.CAN-11-4135","volume":"72","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012;72:3153\u201362.","journal-title":"Cancer Res"},{"key":"2520_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/2326-6066.CIR-16-0141","volume":"5","author":"HL Peters","year":"2017","unstructured":"Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, et al. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res. 2017;5:319\u201329.","journal-title":"Cancer Immunol Res"},{"key":"2520_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cellimm.2008.10.001","volume":"255","author":"C Stoeckle","year":"2009","unstructured":"Stoeckle C, Sommandas V, Adamopoulou E, Belisle K, Schiekofer S, Melms A, et al. Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cell Immunol. 2009;255:41\u201345.","journal-title":"Cell Immunol"},{"key":"2520_CR54","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.4049\/jimmunol.172.9.5495","volume":"172","author":"T Burster","year":"2004","unstructured":"Burster T, Beck A, Tolosa E, Marin-Esteban V, Rotzschke O, Falk K, et al. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. J Immunol. 2004;172:5495\u2013503.","journal-title":"J Immunol"},{"key":"2520_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.molimm.2009.10.003","volume":"47","author":"T Burster","year":"2010","unstructured":"Burster T, Macmillan H, Hou T, Boehm BO, Mellins ED. Cathepsin G: roles in antigen presentation and beyond. Mol Immunol. 2010;47:658\u201365.","journal-title":"Mol Immunol"},{"key":"2520_CR56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0b013e31824b3b14","volume":"35","author":"G Alatrash","year":"2012","unstructured":"Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, et al. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012;35:309\u201320.","journal-title":"J Immunother"},{"key":"2520_CR57","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135.","journal-title":"Blood"},{"key":"2520_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.0105-2896.2005.00275.x","volume":"205","author":"DD Taub","year":"2005","unstructured":"Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005;205:72\u201393.","journal-title":"Immunol Rev"},{"key":"2520_CR59","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1182\/blood.V90.9.3789","volume":"90","author":"FT Hakim","year":"1997","unstructured":"Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789\u201398.","journal-title":"Blood"},{"key":"2520_CR60","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.exphem.2005.06.016","volume":"33","author":"M Jimenez","year":"2005","unstructured":"Jimenez M, Martinez C, Ercilla G, Carreras E, Urbano-Ispizua A, Aymerich M, et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol. 2005;33:1240\u20138.","journal-title":"Exp Hematol"},{"key":"2520_CR61","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5:197ra103.","journal-title":"Sci Transl Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02520-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:54:19Z","timestamp":1744203259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2520"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02520-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5033376\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were performed in accordance with the University of Texas MD Anderson Cancer Center guidelines and regulations for laboratory research. Research approval was obtained through the MD Anderson Cancer Center IRB-approved tissue collection protocol (Protocol# LAB99-062) and IACUC animal protocol (Protocol# 00001336-RN02). Informed consent was obtained from all study participants prior to tissue collection. This study did not contain any direct research on human subjects; only archived human tissue. No identifiable images from human research participants were included in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}